Novigenix SA (Novigenix) is a molecular diagnostics company that develops new generation blood tests for early detection of cancer. The company provides lead product such as colox, a molecular blood test designed to reduce the mortality from colorectal cancer through early detection and colonoscopy. It offers colox which is based on the analysis of peripheral blood mononuclear cells that detects both adenomatous polyps and early stages of colorectal cancer. Novigenix provides technology which is based on a new generation of gene expression profiles of circulating blood cells and tumor-derived protein markers. The company caters through its clinical laboratories located in Switzerland. Novigenix is headquartered in Lausanne, Switzerland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Novigenix SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Novigenix SA Company Overview
- Novigenix SA Company Snapshot
- Novigenix SA Pipeline Products and Ongoing Clinical Trials Overview
- Novigenix SA - Pipeline Analysis Overview
- Novigenix SA - Key Facts
- Novigenix SA - Major Products and Services
- Novigenix SA Pipeline Products by Development Stage
- Novigenix SA Pipeline Products Overview
- LITOSeek - Urothelial Cancer
- LITOSeek - Urothelial Cancer Product Overview
- LITOSeekColon
- LITOSeekColon Product Overview
- LITOseekColonMon
- LITOseekColonMon Product Overview
- LITOSeekProstate
- LITOSeekProstate Product Overview
- Precision Diagnostic Test - Neuroendocrine Tumor
- Precision Diagnostic Test - Neuroendocrine Tumor Product Overview
- Novigenix SA - Key Competitors
- Novigenix SA - Key Employees
- Novigenix SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Affiliate
- Recent Developments
- Novigenix SA, Recent Developments
- Mar 11, 2025: New Study Reveals Novel Multi-Omics Approach With Unprecedented Treatment Response Prediction in Metastatic Urothelial Cancer
- Sep 24, 2024: Prostate cancer breakthrough: Novigenix-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology
- Apr 22, 2024: Revolutionizing Colorectal Cancer Screening with Novigenix Innovations
- Jan 17, 2024: Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
- Jun 30, 2023: Novigenix Reports Interim European Validation Data on Its New NGS-Based Whole Blood RNA Signature for Detection of Advanced Colorectal Adenomas
- Sep 09, 2022: Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma
- Sep 23, 2021: Novigenix and Radbound University Medical Center discover the first blood-based ImmunoTranscriptomic biomarkers for Response to anti-PD-1 therapy
- Dec 22, 2020: Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test
- Jan 21, 2020: Novigenix-Led Consortium secures Eurostars Funding to develop multi-omics test for colon cancer detection and monitoring
- Dec 11, 2019: Novigenix develops new NGS-based immune cell type specific RNA signatures for early colon cancer detection
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Novigenix SA Pipeline Products and Ongoing Clinical Trials Overview
- Novigenix SA Pipeline Products by Equipment Type
- Novigenix SA Pipeline Products by Indication
- Novigenix SA, Key Facts
- Novigenix SA, Major Products and Services
- Novigenix SA Number of Pipeline Products by Development Stage
- Novigenix SA Pipeline Products Summary by Development Stage
- LITOSeek - Urothelial Cancer - Product Status
- LITOSeek - Urothelial Cancer - Product Description
- LITOSeekColon - Product Status
- LITOSeekColon - Product Description
- LITOseekColonMon - Product Status
- LITOseekColonMon - Product Description
- LITOSeekProstate - Product Status
- LITOSeekProstate - Product Description
- Precision Diagnostic Test - Neuroendocrine Tumor - Product Status
- Precision Diagnostic Test - Neuroendocrine Tumor - Product Description
- Novigenix SA, Key Employees
- Novigenix SA, Affiliate
- Glossary
- Novigenix SA Pipeline Products by Equipment Type
- Novigenix SA Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nanolive SA
- Aptuit Switzerland AG
- Numab AG
- Clemedi AG
